Stockscreener 앱 받기
737.45
0.90%
-6.67
시간 외 거래:
737.27
-0.18
-0.02%
전일 마감가:
$744.12
열려 있는:
$744.5
하루 거래량:
627.87K
Relative Volume:
0.82
시가총액:
$77.96B
수익:
$14.34B
순이익/손실:
$4.50B
주가수익비율:
17.74
EPS:
41.5626
순현금흐름:
$3.77B
1주 성능:
-1.23%
1개월 성능:
-5.74%
6개월 성능:
+24.57%
1년 성능:
+9.68%
1일 변동 폭
$727.88
$750.32
1주일 범위
$727.88
$771.23
52주 변동 폭
$476.49
$821.11
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-06 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead? - The Globe and Mail
Formycon secures license date for aflibercept biosimilar FYB203 in Europe - The Pharma Letter
Hudson Bay Capital Management LP Sells 31,367 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Groupama Asset Managment Sells 5,169 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Lower LDL Is Better In New ACC/AHA Guidelines, Making The Case For Add-Ons To Statins - Citeline News & Insights
Trading Action: What are the future prospects of Regeneron Pharmaceuticals Inc2026 Volume Leaders & AI Driven Stock Reports - baoquankhu1.vn
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
Caerus Investment Advisors LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
BAYRY Reports Positive Data on Kidney Drug in Non-Diabetic CKD - The Globe and Mail
Regeneron: EPS Set to Jump 18% in 2027 as Obesity Bet Reframes the Investment Case - TIKR.com
Holocene Advisors LP Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Brevan Howard Capital Management LP Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
California Public Employees Retirement System Sells 111,602 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Boothbay Fund Management LLC Buys 1,541 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Behavioral Patterns of REGN and Institutional Flows - Stock Traders Daily
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron and Sanofi Extend Phase 3 Itepekimab Program in Chronic Sinus Disease - TipRanks
Hamilton Wealth LLC Acquires New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Gotham Asset Management LLC Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Distillate Capital Partners LLC - MarketBeat
Aquatic Capital Management LLC Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Alliancebernstein L.P. Sells 63,344 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy? - Insider Monkey
Bank of Nova Scotia Boosts Regeneron Pharmaceuticals Holdings - National Today
Capitolis Liquid Global Markets LLC Sells 93,000 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Chevy Chase Trust Holdings LLC Lowers Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bank of Nova Scotia Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (REGN) Valuation Check After Recent Share Price Cooling - simplywall.st
Suvretta Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Dodge & Cox - MarketBeat
Cash per share of Regeneron Pharmaceuticals, Inc. – HAM:RGO - TradingView
Game Creek Capital LP Has $2.77 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Tocqueville Asset Management L.P. Sells 6,884 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Hits Day Low of $744 Amid Price Pressure - Markets Mojo
Regeneron Pharmaceuticals Inc Stock (ISIN: US7739031091) Faces Pressure Amid R&D Surge and Margin Sq - AD HOC NEWS
Quadrature Capital Ltd Has $34.31 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push - AOL.com
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
The U.S. Food and Drug Administration (FDA) has officially approved Regeneron Pharmaceuticals' Eylea HD for the treatment of a rare pediatric disease. - Bitget
Quadrant Capital Boosts Regeneron Pharmaceuticals Holdings - National Today
Mackenzie Financial Corp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Capital Research Global Investors Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - AOL.com
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years - AOL.com
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Positive Obesity Phase 3 Trial Results - Yahoo Finance
Regeneron Science Talent Search: Jericho High senior Ashka Shah recounts experience at finals in D.C. - Newsday
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.04%
1.43%
자본화:
|
볼륨(24시간):